Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9061130 | 0.86 | LMNA (0.54) | LMNABCAT2L3MBTL1KDM4ENPC1 | |
| SCHEMBL3096495 | 0.85 | KYNU (0.52) | CNR2LMNAKDM4ERAB9AMEN1 | |
| SCHEMBL3102141 | 0.81 | TRPA1 (0.65) | L3MBTL1SMN1; SMN2HDAC8HDAC6SLC6A3 | |
| SCHEMBL21944189 | 0.80 | TSHR (0.53) | CNR2CES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL3091093 | 0.79 | TRPA1 (0.55) | LMNACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10870293 | 0.78 | LMNA (0.57) | LMNABCAT2L3MBTL1KDM4ENPC1 | |
| SCHEMBL13545233 | 0.78 | LMNA (0.57) | LMNABCAT2L3MBTL1KDM4ENPC1 | |
| SCHEMBL8383947 | 0.78 | LMNA (0.57) | LMNABCAT2L3MBTL1KDM4ENPC1 | |
| SCHEMBL5384514 | 0.78 | KDM4E (0.50) | LMNABCAT2L3MBTL1KDM4ENPC1 | |
| SCHEMBL5384511 | 0.78 | KDM4E (0.50) | LMNABCAT2L3MBTL1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| EP-2227449-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | Pulkkinen, Juha (FI) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009066008-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009066008-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | HSD17B11, HSD17B7, CYP19A1 | CNR2 2214/4885CES2 1675/4885CES1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.